Waitan Ludi Policy Terminal

Country-interest evidence · pilot

Trade inferences use UN Comtrade, with China as reporter. Country connections indicate potential trade relevance, not measured harm, firm-level exposure or legal applicability. Inward measures concern exporters to China; competition with Chinese exports in third markets is not assessed.

Inspect implementing jurisdictions and partner evidence · 51 relationships

Implementing jurisdiction: China · intervention 62523

Australia: Trade-based inference; exporters to China; summed product trade > USD 1m; 2023 trade; broad sector headings; computed, not analyst-reviewed · intervention 62524 · recorded trade USD 159,757,769

Austria: Trade-based inference; exporters to China; summed product trade > USD 1m; 2023 trade; broad sector headings; computed, not analyst-reviewed · intervention 62524 · recorded trade USD 196,071,895

Belgium: Trade-based inference; exporters to China; summed product trade > USD 1m; 2023 trade; broad sector headings; computed, not analyst-reviewed · intervention 62524 · recorded trade USD 29,040,248

Bulgaria: Trade-based inference; exporters to China; summed product trade > USD 1m; 2023 trade; broad sector headings; computed, not analyst-reviewed · intervention 62524 · recorded trade USD 8,576,763

Brazil: Trade-based inference; exporters to China; summed product trade > USD 1m; 2023 trade; broad sector headings; computed, not analyst-reviewed · intervention 62524 · recorded trade USD 10,741,658

Barbados: Trade-based inference; exporters to China; summed product trade > USD 1m; 2023 trade; broad sector headings; computed, not analyst-reviewed · intervention 62524 · recorded trade USD 11,371,623

Canada: Trade-based inference; exporters to China; summed product trade > USD 1m; 2023 trade; broad sector headings; computed, not analyst-reviewed · intervention 62524 · recorded trade USD 103,072,477

Switzerland: Trade-based inference; exporters to China; summed product trade > USD 1m; 2023 trade; broad sector headings; computed, not analyst-reviewed · intervention 62524 · recorded trade USD 990,686,635

Costa Rica: Trade-based inference; exporters to China; summed product trade > USD 1m; 2023 trade; broad sector headings; computed, not analyst-reviewed · intervention 62524 · recorded trade USD 607,811,874

Czech Republic: Trade-based inference; exporters to China; summed product trade > USD 1m; 2023 trade; broad sector headings; computed, not analyst-reviewed · intervention 62524 · recorded trade USD 103,258,057

Germany: Trade-based inference; exporters to China; summed product trade > USD 1m; 2023 trade; broad sector headings; computed, not analyst-reviewed · intervention 62524 · recorded trade USD 3,546,832,348

Denmark: Trade-based inference; exporters to China; summed product trade > USD 1m; 2023 trade; broad sector headings; computed, not analyst-reviewed · intervention 62524 · recorded trade USD 120,266,147

Dominican Republic: Trade-based inference; exporters to China; summed product trade > USD 1m; 2023 trade; broad sector headings; computed, not analyst-reviewed · intervention 62524 · recorded trade USD 128,945,891

Spain: Trade-based inference; exporters to China; summed product trade > USD 1m; 2023 trade; broad sector headings; computed, not analyst-reviewed · intervention 62524 · recorded trade USD 20,567,417

Estonia: Trade-based inference; exporters to China; summed product trade > USD 1m; 2023 trade; broad sector headings; computed, not analyst-reviewed · intervention 62524 · recorded trade USD 1,805,022

Finland: Trade-based inference; exporters to China; summed product trade > USD 1m; 2023 trade; broad sector headings; computed, not analyst-reviewed · intervention 62524 · recorded trade USD 56,766,490

France: Trade-based inference; exporters to China; summed product trade > USD 1m; 2023 trade; broad sector headings; computed, not analyst-reviewed · intervention 62524 · recorded trade USD 384,372,751

United Kingdom: Trade-based inference; exporters to China; summed product trade > USD 1m; 2023 trade; broad sector headings; computed, not analyst-reviewed · intervention 62524 · recorded trade USD 349,914,614

Hong Kong, China: Trade-based inference; exporters to China; summed product trade > USD 1m; 2023 trade; broad sector headings; computed, not analyst-reviewed · intervention 62524 · recorded trade USD 1,920,300

Hungary: Trade-based inference; exporters to China; summed product trade > USD 1m; 2023 trade; broad sector headings; computed, not analyst-reviewed · intervention 62524 · recorded trade USD 13,552,028

Indonesia: Trade-based inference; exporters to China; summed product trade > USD 1m; 2023 trade; broad sector headings; computed, not analyst-reviewed · intervention 62524 · recorded trade USD 4,399,447

India: Trade-based inference; exporters to China; summed product trade > USD 1m; 2023 trade; broad sector headings; computed, not analyst-reviewed · intervention 62524 · recorded trade USD 146,820,102

Ireland: Trade-based inference; exporters to China; summed product trade > USD 1m; 2023 trade; broad sector headings; computed, not analyst-reviewed · intervention 62524 · recorded trade USD 896,955,653

Iceland: Trade-based inference; exporters to China; summed product trade > USD 1m; 2023 trade; broad sector headings; computed, not analyst-reviewed · intervention 62524 · recorded trade USD 4,692,026

Israel: Trade-based inference; exporters to China; summed product trade > USD 1m; 2023 trade; broad sector headings; computed, not analyst-reviewed · intervention 62524 · recorded trade USD 456,495,464

Italy: Trade-based inference; exporters to China; summed product trade > USD 1m; 2023 trade; broad sector headings; computed, not analyst-reviewed · intervention 62524 · recorded trade USD 182,318,179

Japan: Trade-based inference; exporters to China; summed product trade > USD 1m; 2023 trade; broad sector headings; computed, not analyst-reviewed · intervention 62524 · recorded trade USD 1,754,694,082

Korea, Rep.: Trade-based inference; exporters to China; summed product trade > USD 1m; 2023 trade; broad sector headings; computed, not analyst-reviewed · intervention 62524 · recorded trade USD 675,601,723

Lithuania: Trade-based inference; exporters to China; summed product trade > USD 1m; 2023 trade; broad sector headings; computed, not analyst-reviewed · intervention 62524 · recorded trade USD 1,551,130

Mexico: Trade-based inference; exporters to China; summed product trade > USD 1m; 2023 trade; broad sector headings; computed, not analyst-reviewed · intervention 62524 · recorded trade USD 2,160,180,475

Malaysia: Trade-based inference; exporters to China; summed product trade > USD 1m; 2023 trade; broad sector headings; computed, not analyst-reviewed · intervention 62524 · recorded trade USD 268,897,003

Netherlands: Trade-based inference; exporters to China; summed product trade > USD 1m; 2023 trade; broad sector headings; computed, not analyst-reviewed · intervention 62524 · recorded trade USD 674,899,058

Norway: Trade-based inference; exporters to China; summed product trade > USD 1m; 2023 trade; broad sector headings; computed, not analyst-reviewed · intervention 62524 · recorded trade USD 38,144,780

New Zealand: Trade-based inference; exporters to China; summed product trade > USD 1m; 2023 trade; broad sector headings; computed, not analyst-reviewed · intervention 62524 · recorded trade USD 43,805,362

Pakistan: Trade-based inference; exporters to China; summed product trade > USD 1m; 2023 trade; broad sector headings; computed, not analyst-reviewed · intervention 62524 · recorded trade USD 11,617,789

Philippines: Trade-based inference; exporters to China; summed product trade > USD 1m; 2023 trade; broad sector headings; computed, not analyst-reviewed · intervention 62524 · recorded trade USD 17,678,452

Poland: Trade-based inference; exporters to China; summed product trade > USD 1m; 2023 trade; broad sector headings; computed, not analyst-reviewed · intervention 62524 · recorded trade USD 48,263,556

Romania: Trade-based inference; exporters to China; summed product trade > USD 1m; 2023 trade; broad sector headings; computed, not analyst-reviewed · intervention 62524 · recorded trade USD 11,031,212

Russian Federation: Trade-based inference; exporters to China; summed product trade > USD 1m; 2023 trade; broad sector headings; computed, not analyst-reviewed · intervention 62524 · recorded trade USD 3,000,731

Singapore: Trade-based inference; exporters to China; summed product trade > USD 1m; 2023 trade; broad sector headings; computed, not analyst-reviewed · intervention 62524 · recorded trade USD 278,206,148

Slovak Republic: Trade-based inference; exporters to China; summed product trade > USD 1m; 2023 trade; broad sector headings; computed, not analyst-reviewed · intervention 62524 · recorded trade USD 2,683,215

Slovenia: Trade-based inference; exporters to China; summed product trade > USD 1m; 2023 trade; broad sector headings; computed, not analyst-reviewed · intervention 62524 · recorded trade USD 18,782,036

Sweden: Trade-based inference; exporters to China; summed product trade > USD 1m; 2023 trade; broad sector headings; computed, not analyst-reviewed · intervention 62524 · recorded trade USD 127,730,736

Thailand: Trade-based inference; exporters to China; summed product trade > USD 1m; 2023 trade; broad sector headings; computed, not analyst-reviewed · intervention 62524 · recorded trade USD 119,696,136

Tunisia: Trade-based inference; exporters to China; summed product trade > USD 1m; 2023 trade; broad sector headings; computed, not analyst-reviewed · intervention 62524 · recorded trade USD 1,024,303

Turkey: Trade-based inference; exporters to China; summed product trade > USD 1m; 2023 trade; broad sector headings; computed, not analyst-reviewed · intervention 62524 · recorded trade USD 49,716,495

Chinese Taipei: Trade-based inference; exporters to China; summed product trade > USD 1m; 2023 trade; broad sector headings; computed, not analyst-reviewed · intervention 62524 · recorded trade USD 138,213,158

United States: Trade-based inference; exporters to China; summed product trade > USD 1m; 2023 trade; broad sector headings; computed, not analyst-reviewed · intervention 62524 · recorded trade USD 5,314,012,971

Vietnam: Trade-based inference; exporters to China; summed product trade > USD 1m; 2023 trade; broad sector headings; computed, not analyst-reviewed · intervention 62524 · recorded trade USD 369,668,821

Implementing jurisdiction: China · intervention 62524

Assessment states

No sector coded; treated as horizontal by the source calculation (not independently confirmed)
Trade-based partners recorded

Measures

Capital grant

County · origin: Chinese firms or production in China · locality: Local firms · in force from 2024-12-03 · until 2027-12-31 · Keyword screen (unreviewed)

Implemented by China (subnational) · no affected jurisdictions listed: no sector named, so treated as horizontal: no affected jurisdictions

Stated rationale

Public health & product safety · document title or opening · unreviewed 普陀区加快发展生命健康产业实施意见

对年经营规模首次突破5000万元、1亿元、3亿元的生命健康流通销售企业，分别给予10万元、20万元、40万元的奖励。

Supports production in a place, so favours that place by rule.

Local production condition

County · origin: Chinese firms or production in China · locality: Local firms · CPC 481 · in force from 2024-12-03 · until 2027-12-31 · Keyword screen (unreviewed)

Implemented by China (subnational) · affects 49 partners (inferred from trade data, 2023 trade): United States, Germany, Mexico, Japan, Switzerland, Ireland …

Stated rationale

Public health & product safety · document title or opening · unreviewed 普陀区加快发展生命健康产业实施意见

对进入国家和本市创新医疗器械特别审查程序的医疗器械产品，或进入上述程序、首次取得医疗器械注册证并在本区生产的产品，获得市相关部门立项的，按照市级资助金额最高50%给予配套支持。

Asymmetric provisions

Local production requirement (本地生产)

Disadvantages: imports firms from other regions · Keyword screen (unreviewed)

Full text

印发日期：2024-12-03普商务规范〔2024〕2号为贯彻落实《“健康中国”2030规划纲要》《关于支持生物医药产业全链条创新发展的若干意见》等文件精神，按照区委、区政府工作部署，主动抢抓生命健康发展机遇，加快推动普陀区生命健康产业高质量发展，着力打造立足上海、辐射长三角、面向国际的生命健康总部基地、高端医学创新中心、医药资源配置中心、数字医疗服务中心，结合本区实际，制定本意见。一、扶持对象本意见主要支持信用记录良好、符合区域产业导向的生命健康领域企业和与之相关的配套服务企业，以及经区生命健康产业相关工作部门认定后列入支持范围的生命健康产业相关项目。二、扶持方式 (一)支持企业规模化发展 1、鼓励优质企业发展。对区域产业发展具有明显带动和支撑作用的优质企业，经认定，给予最高不超过800万元资助，分三年拨付。 2、鼓励研发创新型企业集聚。对新引进的研发服务外包(CRO)、研发生产外包(CMO、CDMO)等研发创新型重点企业，经认定，按照引进后两年创新研发费用的30%，给予一次性最高不超过500万元支持。 3、支持企业规模化发展。对年经营规模首次突破5000万元、1亿元、3亿元的生命健康流通销售企业，分别给予10万元、20万元、40万元的奖励。对年经营规模首次突破5亿元的生命健康流通销售企业给予50万元的奖励;晋档期间，按照年经营规模较上一年度经营规模新增额最高0.1%的比例给予奖励。对年经营规模首次突破10亿元、30亿元、50亿元的生命健康流通销售企业分别给予100万元、200万元、300万元的奖励;晋档期间，按照年经营规模较上一年度经营规模新增额最高0.05%的比例给予奖励。 (二)支持企业创新化发展 4、支持专业服务平台建设。鼓励在本区建设研发中心、开放创新中心、技术研究院、检验检测、孵化转化等专业服务平台和重点实验室、产业技术基础公共服务平台等科技研发平台，开展技术赋能、产业链协同、集团研发统筹等，对形成一定的行业和区域示范引领效果的，经认定，给予最高不超过200万元的一次性资助;鼓励本区研发服务平台为本区企业提供生命健康研发及生产的专业化服务，按认定实际服务额的10%给予资助，年度最高不超过300万元。 5、支持医疗器械研发上市。对进入国家和本市创新医疗器械特别审查程序的医疗器械产品，或进入上述程序、首次取得医疗器械注册证并在本区生产的产品，获得市相关部门立项的，按照市级资助金额最高50%给予配套支持。对申报年度首次获得二类医疗器械注册证的，给予最高100万元支持。对申报年度首次获得三类医疗器械注册证的，给予最高300万元支持。同一医疗器械不同规格视为同一品种。单个企业年度累计最高不超过300万元。 (三)支持企业协同化发展 6、激励产学研医合作和成果转移转化。鼓励企业联合高校、医院、科研院所开展技术研发攻关，经认定，按照项目研发投入30%给予最高不超过300万元资助。支持企业运用高校院所科技成果进行产业化，经认定，按项目投入的30%给予资助，最高不超过300万元。 7、推动药品上市许可持有人、医疗器械注册人试点落地。对取得药品上市许可持有人或医疗器械注册人资格的单位(在本区无生产基地)，按照申报品种较上一年度新增销售收入最高1%的比例给予奖励，最高不超过300万元。对区内获得药品上市许可持有人或医疗器械注册人授权委托生产的单位(与持有人无投资关系)，按照该品种较上一年度产值新增额最高0.5%的比例给予奖励，最高不超过200万元。 8、鼓励企业创新产品及服务投入市场。对企业申报年度高端医疗器械首台、列入《上海市创新产品推荐目录》产品、上海市“新优药械”产品，按照首笔销售合同金额的10%进行资助，最高不超过100万元。 9、加快“智慧医疗”发展。支持生物医药与大数据、云计算、人工智能等新一代信息技术相融合;支持企业与本区医疗服务机构加强医疗大数据应用、精准医学研究等领域合作;支持5G+智慧医疗、医疗器械数字化、智能化，重点开发可穿戴、便携式等移动医疗和辅助器具产品;鼓励生物三维(3D)打印技术、数据芯片等新技术在植介入产品重点的应用。对经认定的项目，按照项目研发投入不超过30%最高不超过200万元给予支持。 (四)优化产业发展环境 10、鼓励企业参办国际化论坛会展活动。鼓励企业在本区举办有较大影响力的专业化、国际化高端论坛等活动，经认定，按照实际发生金额的80%，可给予最高不超过200万元资助。支持企业参加国际、国内知名会展，经认定，按照注册费、展位费、搭建费实际发生额的50%，可给予最高不超过20万元资助。 11、提升行政审批服务效能。进一步优化企业帮办机制，在登记许可环节提供优质高效服务，为企业个性化问题提供定制解决方案。 12、积极发挥区产业创新发展引导基金作用。通过引导基金与社会资本合作，吸引各类金融机构、社会资本助力区内生命健康企业发展，引导所投子基金向本区导入优质生命健康项目。 13、支持创新创业载体建设。支持高校、医院和科研院所引导创新企业集聚，建设创新创业载体，按照运营情况，给予运营主体一定奖励。 14、由区投资促进领导小组认定的，对生命健康产业发展具有引领和带动作用的重大项目，经认定，给予一定资金资助。三、使用管理 1、区商务委会同区各责任部门，根据本意见制定实施流程和细则，落实项目审核、跟踪、评估等工作。本政策条款若与上海市、普陀区制定的其他政策有重复交叉的，按照“从高不重复”原则予以支持。 2、各地区投促中心负责为申报单位提供扶持项目申请、初审等服务，在政策实施部门完成项目审核后负责向申报单位答复，并配合实施部门做好项目管理服务工作。 3、区商务委负责编制年度专项资金预算，并按程序向区财政局申请拨款，区财政局负责执行相关扶持资金的拨付，在项目过程中会同审计部门对专项资金的使用管理情况进行监督管理。 4、本意见按照《普陀区产业政策绩效评估管理办法》，实行绩效评估管理。四、附则 1、实行产业专项资金全过程信用管理。申请本政策扶持的企业或机构，将接受信用审查，过去三年内存在严重失信行为或违法行为的，取消申请资格。企业或机构在享受扶持过程中存在失信行为，经查实的，按照有关规定报送市、区公共信用信息服务平台。扶持对象存在弄虚作假、骗取扶持资金等违法违规行为，经查实的，将立即取消一切扶持资金并追缴资金，依法追究相关责任。 2、本意见自发布之日起施行，有效期至2027年12月31日，《普陀区加快发展生命健康产业实施意见》(普商务规范〔2021〕4号)同时废止。上海市普陀区商务委员会上海市普陀区发展和改革委员会上海市普陀区科学技术委员会上海市普陀区财政局上海市普陀区卫生健康委员会上海市普陀区市场监督管理局上海市普陀区医疗保障局上海市普陀区投资促进办公室 2024年12月3日